Trial Profile
A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with Chemotherapy (Tumor-DNA Damaging Agent) for the Treatment of Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Nov 2023
Price :
$35
*
At a glance
- Drugs Etidaligide (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms DRIIV-1b
- Sponsors Valerio Therapeutics
- 09 Nov 2020 Status changed from recruiting to active, no longer recruiting, according to an Onxeo SA media release.
- 09 Nov 2020 Interim results published in Onxeo SA Media Release.
- 09 Nov 2020 According to an Onxeo SA media release, it announced the completion of enrollment and the last patient was treated.